Difference between revisions of "OCT3/4"
Jump to navigation
Jump to search
| Line 5: | Line 5: | ||
*[[Embryonal carcinoma]]. | *[[Embryonal carcinoma]]. | ||
*[[Germ cell neoplasia in situ]]. | *[[Germ cell neoplasia in situ]]. | ||
*[[Renal medullary carcinoma]].<ref name=pmid22301499>{{cite journal | | *[[Renal medullary carcinoma]].<ref name=pmid22301499>{{cite journal |authors=Rao P, Tannir NM, Tamboli P |title=Expression of OCT3/4 in renal medullary carcinoma represents a potential diagnostic pitfall |journal=Am J Surg Pathol |volume=36 |issue=4 |pages=583–8 |date=April 2012 |pmid=22301499 |doi=10.1097/PAS.0b013e3182417d78 |url=}}</ref> | ||
*[[Prostatic adenocarcinoma]]. | *[[Prostatic adenocarcinoma]]. | ||
*[[Mucoepidermoid carcinoma]]. | *[[Mucoepidermoid carcinoma]]. | ||
Revision as of 20:35, 5 March 2021
OCT3/4 is a common immunostain used in the work-up of germ cell tumours.
Positive
- Seminoma.
- Embryonal carcinoma.
- Germ cell neoplasia in situ.
- Renal medullary carcinoma.[1]
- Prostatic adenocarcinoma.
- Mucoepidermoid carcinoma.
- Non-small cell lung carcinoma.
Negative
See also
References
- ↑ Rao P, Tannir NM, Tamboli P (April 2012). "Expression of OCT3/4 in renal medullary carcinoma represents a potential diagnostic pitfall". Am J Surg Pathol 36 (4): 583–8. doi:10.1097/PAS.0b013e3182417d78. PMID 22301499.